2014/05/31 by Erkut Borazanci, Daniel D. Von Hoff · 1 citation
Medicine · #Pancreatic and Hepatic Oncology Research #Neuroendocrine Tumor Research Advances #Renal cell carcinoma treatment
paper · doi:10.1586/17474124.2014.925799
openalex publication_date 2014/05/31 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/29
Adenocarcinoma of the pancreas or pancreatic cancer as we will refer to it here, is a cancer of poor prognosis with a high mortality, particularly in the advanced or metastatic setting. Until 2011 and the Phase III results of FOLFIRINOX, standard treatment options were limited to gemcitabine. Combination therapy had shown either a lack of or very limited improvement versus monotherapy with gemcitabine. With the positive results of the MPACT study in 2013 showing improved survival with nab-paclitaxel plus gemcitabine combination therapy, there are now more options for oncologists to treat patients with advanced pancreatic cancer. This paper will highlight the Phase I/II and Phase III trials of nab-paclitaxel plus gemcitabine along with discussing their biology and further possible development in treating patients with pancreatic cancer.